Summary
BIIB Chart
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise
Biogen Inc. Dividends
 BIIB 2 Feb 2017 Paid | Other | $22.23 Per Share |
Biogen Inc. Earnings
| 30 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 22 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 3.36 Cons. EPS | 3.44 EPS |
| 6 Nov 2024 Date | | 3.79 Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 3.79 Cons. EPS | 4.08 EPS |
| BIIB 2 Feb 2017 Paid | Other | $22.23 Per Share |
| 30 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 22 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 3.36 Cons. EPS | 3.44 EPS |
| 6 Nov 2024 Date | | 3.79 Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 3.79 Cons. EPS | 4.08 EPS |
Biogen Inc. (BIIB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Biogen Inc. ever had a stock split?
Biogen Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Christopher A. Viehbacher CEO | XWBO Exchange | US09062X1037 ISIN |
| US Country | 7,605 Employees | - Last Dividend | 18 Jan 2001 Last Split | 16 Sep 1991 IPO Date |
Overview
Biogen Inc. is a pioneering biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a broad international presence, Biogen extends its reach across the United States, Europe, Germany, Asia, and other global regions. Since its founding in 1978, Biogen has been at the forefront of addressing some of the most challenging medical conditions, including multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, and psoriasis, among others. The company operates in collaboration with several notable industry partners, such as Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; and others, to advance its mission of transforming scientific discoveries into medical breakthroughs. Headquartered in Cambridge, Massachusetts, Biogen's commitment to improving patient care continues to drive its innovative research and drug development strategies.
Products and Services
Biogen's diverse portfolio showcases its dedication to treating complex neurological and neurodegenerative conditions:
- TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA: These products are part of Biogen's multiple sclerosis (MS) treatment range, addressing various aspects of MS management to improve patient quality of life.
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy, offering hope to individuals affected by this genetic disorder.
- ADUHELM: Part of Biogen's Alzheimer's disease portfolio, this drug represents a significant advancement in treating a condition that affects millions of individuals worldwide.
- FUMADERM: Developed for the treatment of plaque psoriasis, demonstrating Biogen's commitment to addressing autoimmune skin conditions.
- Biosimilars (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ): These etanercept, adalimumab, infliximab, and ranibizumab biosimilars offer cost-effective alternatives to some of the most widely used biologic therapies for autoimmune diseases and macular degeneration.
- RITUXAN (and RITUXAN HYCELA), GAZYVA, OCREVUS: Biogen's offerings in the oncology and MS spaces, including treatments for non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, and primary progressive MS, highlight the company's strong presence in developing therapies for both cancer and autoimmune diseases.
- LUNSUMIO, glofitamab, and other anti-CD20 therapies: These therapies are designed for patients with relapsed or refractory follicular lymphoma and non-Hodgkin's lymphoma, showcasing Biogen’s ongoing dedication to innovative cancer treatment.
In addition, Biogen's pipeline includes a broad array of projects targeting MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, neuropsychiatry, genetic neurodevelopmental disorders, and the development of biosimilars. These initiatives, under various stages of development, signify Biogen's enduring commitment to expanding its impact on unmet medical needs and improving the lives of patients around the globe.
Contact Information
